Login to Your Account



Preclinical Oncogene Target

Loxo Winner: Array's Cancer Pact Valued as High as $434M

By Randy Osborne
Staff Writer

Thursday, July 11, 2013
Newly formed by the venture firm Aisling Capital, Loxo Oncology Inc. has entered a deal with Array Biopharma Inc. to advance a preclinical candidate developed by Array and to find more small-molecule drugs for oncology targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription